We continue to evaluate new in-licensing and acquisition opportunities to further expand our pipeline of novel, differentiated and disruptive programs.
We focus on drug candidates that:
- Satisfy an unmet human need or provide a newer, improved alternative to existing therapies
- Have demonstrated positive results in animal disease models or human studies
- Are capable of or have been patent protected
- Possess significant sales potential in major global markets
If you have a technology that you believe may be of interest to us, please email info@brickellbio.com.